Abstract
This study assessed whether behavioral differences explained higher human immunodeficiency virus (HIV) seroprevalence among injection drug users (IDUs) in three East Coast versus two West Coast cities in the United States. Sociodemographic, sexual, and injecting information were collected during semiannual face-to-face interviews. Baseline data from New York City; Baltimore, Maryland; and New Haven, Connecticut, were compared with data from Los Angeles, California, and San Jose, California. Among 1,528 East Coast and 1,149 West Coast participants, HIV seroprevalence was 21.5% and 2.3%, respectively (odds ratio [OR] 11.9; 95% confidence interval [CI] 7.9–17.8). HIV risk behaviors were common among IDUs on both coasts, and several were more common among West Coast participants. Adjusting for potential risk factors, East (vs. West) Coast of residence remained highly associated with HIV status (adjusted OR 12.14; 95% CI 7.36–20.00). Differences in HIV seroprevalence between East and West Coast cities did not reflect self-reported injection or sexual risk behavior differences. This suggests that other factors must be considered, such as the probability of having HIV-infected injection or sexual partners. Prevention efforts are needed on the West Coast to decrease HIV-associated risk behaviors among IDUs, and further efforts are also needed to reduce HIV incidence on the East Coast.
Keywords: Epidemiology, Human immunodeficiency virus, Incidence, Injection drug use, Prevalence, Risk factors
Full Text
The Full Text of this article is available as a PDF (77.8 KB).
References
- 1.Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–654. doi: 10.2105/ajph.86.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108–112. doi: 10.2105/ajph.88.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. J Acquir Immune Defic Syndr Human Retrovirol. 2000;25:63–70. doi: 10.1097/00042560-200009010-00009. [DOI] [PubMed] [Google Scholar]
- 4.Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Problems. 1989;36:416–430. [Google Scholar]
- 5.Biernacki P, Waldorf D. Snowball sampling: problems and techniques in chain-referral sampling. Soc Methods Res. 1981;10:141–163. [Google Scholar]
- 6.Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261:1008–1012. doi: 10.1001/jama.261.7.1008. [DOI] [PubMed] [Google Scholar]
- 7.Neaigus A, Friedman SR, Jose B, et al. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J Acquir Immune Defic Syndr Human Retrovirol. 1996;11:499–509. doi: 10.1097/00042560-199604150-00011. [DOI] [PubMed] [Google Scholar]
- 8.Byers RH, Jr, Morgan M, Darrow WW, et al. Estimating AIDS infection rates in the San Francisco Cohort. AIDS. 1988;2:207–10. doi: 10.1097/00002030-198800001-00031. [DOI] [PubMed] [Google Scholar]
- 9.Winkelstein WW, Jr, Samuel M, Padian NS, et al. The San Francisco Men’s Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982–6. Am J Public Health. 1987;77:685–689. doi: 10.2105/AJPH.77.6.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Weniger BG, Limpakrnjanarat K, Ungchusak K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS. 1991;5(suppl 2):S71–S76. doi: 10.1097/00002030-199101001-00011. [DOI] [PubMed] [Google Scholar]
- 11.Jain MK, John JT, Keusch GT. Epidemiology of HIV and AIDS in India. AIDS. 1994;8(suppl 2):S61–S67. [PubMed] [Google Scholar]
- 12.Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr Human Retrovirol. 1999;22:194–199. doi: 10.1097/00126334-199910010-00013. [DOI] [PubMed] [Google Scholar]
- 13.Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385–387. doi: 10.2105/ajph.92.3.385. [DOI] [PMC free article] [PubMed] [Google Scholar]